FindTrial
Sign In

Pemazyre 9 mg tablets

DRUG2 trials

Sponsors

Incyte Corp., Incyte Corp., Incyte Corp.

Conditions

CholangiocarcinomaMale and female participants at least 18 years of age who are actively receiving treatment with pemigatinib under a parent protocol and receiving clinical benefit and who do not have access to pemigatinib outside of a clinical trial

Phase 2

INCB 54828-801: An Open-Label, Multicenter, Rollover Study to Provide Continued Treatment for Participants With Advanced Malignancies Previously Enrolled in Studies of Pemigatinib
CompletedCTIS2023-503406-36-00
Incyte Corp., Incyte Corp.Male and female participants at least 18 years of age who are actively receiving treatment with pemigatinib under a parent protocol and receiving clinical benefit and who do not have access to pemigatinib outside of a clinical trial
Start: 2021-12-13End: 2023-05-11Target: 4Updated: 2023-06-09

Phase 3

A Phase 3, Open-Label, Randomized, Active-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib Versus Gemcitabine Plus Cisplatin Chemotherapy in First-Line Treatment of Participants With Unresectable or Metastatic Cholangiocarcinoma With FGFR2 Rearrangement (FIGHT-302)
CompletedCTIS2024-513513-12-00
Incyte Corp.Cholangiocarcinoma
Start: 2019-01-06End: 2025-06-03Target: 110Updated: 2025-07-23